The ASX-listed investment manager smashed analysts’ expectations thanks to the stellar performance of its growth house.

Brooks Running has outpaced the crowded field of performance footwear thanks to its never-ending chase of perfection. Earlier ...

The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...

Enter NYXI with its updated Hyperion 2 Joy-Con pads, pitched as "the ultimate replacement" for the real Mc-Con. They don't ...

Brooks Running has a mega list of popular shoes on sale for less than $100. Shoppers can grab huge deals on shoes like the ...

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

Merck (MRK) announced the Phase 3 HYPERION study evaluating WINREVAIR versus placebo in recently diagnosed adults with pulmonary arterial ...

Brooks Running often refreshes its markdown page but in a rare deal, the Hyperion is seeing a markdown as low as $84. Originally $140, shoppers can now get 40% off. Runners can track their pace wi ...

In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

In close partnership with ALLIED Feather + Down (AF+D) and premium performance wear manufacturer Active Apparel Group, Templa ...

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.